Portal de Periódicos da CAPES

The cancer-immunity cycle: Indication, genotype, and immunotype

2023; Cell Press; Volume: 56; Issue: 10 Linguagem: Inglês

10.1016/j.immuni.2023.09.011

1097-4180

Ira Mellman, Daniel S. Chen, Thomas Powles, Shannon J. Turley,

CAR-T cell therapy research

The cancer-immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses. It emphasizes the iterative nature of the response where the killing of tumor cells by T cells initiates subsequent rounds of antigen presentation and T cell stimulation, maintaining active immunity and adapting it to tumor evolution. Any step of the cycle can become rate-limiting, rendering the immune system unable to control tumor growth. Here, we update the cancer-immunity cycle based on the remarkable progress of the past decade. Understanding the mechanism of checkpoint inhibition has evolved, as has our view of dendritic cells in sustaining anti-tumor immunity. We additionally account for the role of the tumor microenvironment in facilitating, not just suppressing, the anti-cancer response, and discuss the importance of considering a tumor's immunological phenotype, the "immunotype". While these new insights add some complexity to the cycle, they also provide new targets for research and therapeutic intervention.